Harriet Kluger, M.D., is a physician-scientist and medical oncologist at Yale Cancer Center who specializes in advanced melanoma or renal cell carcinoma. Additionally, the abstract (#389) has been selected by members of the Communications Committee to be presented at the SITC 2021 Annual Meeting Press Conference, which is a virtual session showcasing selected abstracts. The Phase 2 data of sotigalimab in patients with post-anti-PD-(L)1 melanoma will also be presented as a poster at the Society for Immunotherapy of Cancer’s (SITC) 36 th Annual Meeting. To register for the event, please click here. Apexigen's President and Chief Executive Officer, Xiaodong Yang, M.D., Ph.D., will then discuss recent pipeline advancements and provide a corporate update.Ī live Q&A session will follow the formal presentations. Kluger and Apexigen’s Chief Medical Officer, Frank Hsu, M.D., will also lead a discussion on the most recent Phase 2 sotigalimab melanoma data. Kluger will discuss the current treatment landscape and unmet medical need in treating patients with post-anti-PD-(L)1 melanoma and the sotigalimab phase 2 data in post-PD-1(L)1 patients.ĭr. The webinar will feature a presentation by KOL Harriet Kluger, M.D., from the Yale School of Medicine. Sotigalimab is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.
09, 2021 (GLOBE NEWSWIRE) - Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced that it will host a key opinion leader (KOL) webinar on the therapeutic potential of sotigalimab in post-anti-PD-(L)1 melanoma, the Company’s lead immuno-oncology candidate, on Friday, Novemat 11:00 a.m. Data from Phase 2 study to be presented at SITC 2021 Ībstract selected for the Annual Meeting Press Conference.
Featuring Harriet Kluger, M.D., renowned researcher, medical oncologist and lead investigator in the Phase 2 study of sotigalimab in combination therapy for patients with post-anti-PD(L)1 melanoma. Webinar to be held Friday, Novemat 11:00 a.m.